Pharmaceutical

FDA advisory committee reviews Novo Nordisk insulin icodec for T1D

The US FDA's EMDAC is set to hold a meeting to assess the benefit-risk profile of Novo Nordisk's insulin icodec, to treat type 1 diabetes.

May 25, 2024 - 04:00
FDA advisory committee reviews Novo Nordisk insulin icodec for T1D
The US FDA's EMDAC is set to hold a meeting to assess the benefit-risk profile of Novo Nordisk's insulin icodec, to treat type 1 diabetes.
Read the original article

Tags:

Previous Article

ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success

Next Article

Grey Wolf gains $50m boost for antigen modulation tech

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Chamber of Commerce, government clash at first court hearing on Medicare drug prices

STAT+: Chamber of Commerce, government clash at first c...

Sep 16, 2023

STAT+: Bluebird submits sickle cell gene therapy to FDA for approval

STAT+: Bluebird submits sickle cell gene therapy to FDA...

Apr 25, 2023

Oral Solid Dose Manufacturing Companies in the Pharmaceutical Industry

Oral Solid Dose Manufacturing Companies in the Pharmace...

Sep 26, 2024